Plasma Amyloid-Beta Levels in Patients with Different Types of Cancer (original) (raw)

Abstract

Several epidemiological investigations indicate that cancer survivors have a lower risk for Alzheimer’s disease (AD) and vice versa. However, the associations between plasma amyloid-beta (Aβ) levels with cancer remain largely unknown. In this case–control study, 110 cancer patients, 70 AD patients, and 70 age- and gender-matched normal controls were recruited. The cancer types include esophagus cancer, colorectal cancer, hepatic cancer, and lung cancer, all of which were reported to be associated with a lower risk for AD. Plasma levels of Aβ40, Aβ42, common pro-inflammatory cytokines, IL-1β, IL-6, TNF-α, IFN-γ, anti-inflammatory IL-4, chemokines, and cytokines MCP-1 were measured with enzyme-linked immunosorbent assay (ELISA) kits. Plasma levels of Aβ40 and Aβ42 in all cancer patients were higher than that in normal controls. More specifically, hepatic cancer patients exhibited significantly higher plasma Aβ levels. No significant difference in plasma Aβ levels was found between chemotherapy and no chemotherapy subgroups. Plasma Aβ levels were not significantly correlated with pro-inflammatory cytokines, anti-inflammatory, chemokines, and cytokines. Peripheral Aβ levels increased in cancer patients, especially in patients with hepatic cancer, independent of chemotherapy and inflammation. Further verification is required for the association between plasma Aβ and cancer.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

Download references

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant no. 81471296).

Author information

Authors and Affiliations

  1. Department of Neurology and Center for Clinical Neuroscience, Daping Hospital, Third Military Medical University, 10 Changjiang Branch Road, Yuzhong District, Chongqing, China
    Wang-Sheng Jin, Xian-Le Bu, Yu-Hui Liu, Lin-Lin Shen, Zhen-Qian Zhuang, Shu-Sheng Jiao, Chi Zhu, Qing-Hua Wang, Hua-Dong Zhou, Tao Zhang & Yan-Jiang Wang

Authors

  1. Wang-Sheng Jin
    You can also search for this author inPubMed Google Scholar
  2. Xian-Le Bu
    You can also search for this author inPubMed Google Scholar
  3. Yu-Hui Liu
    You can also search for this author inPubMed Google Scholar
  4. Lin-Lin Shen
    You can also search for this author inPubMed Google Scholar
  5. Zhen-Qian Zhuang
    You can also search for this author inPubMed Google Scholar
  6. Shu-Sheng Jiao
    You can also search for this author inPubMed Google Scholar
  7. Chi Zhu
    You can also search for this author inPubMed Google Scholar
  8. Qing-Hua Wang
    You can also search for this author inPubMed Google Scholar
  9. Hua-Dong Zhou
    You can also search for this author inPubMed Google Scholar
  10. Tao Zhang
    You can also search for this author inPubMed Google Scholar
  11. Yan-Jiang Wang
    You can also search for this author inPubMed Google Scholar

Corresponding authors

Correspondence toTao Zhang or Yan-Jiang Wang.

Ethics declarations

This study was approved by the ethics committee of the Daping Hospital (Chongqing, China).

Rights and permissions

About this article

Cite this article

Jin, WS., Bu, XL., Liu, YH. et al. Plasma Amyloid-Beta Levels in Patients with Different Types of Cancer.Neurotox Res 31, 283–288 (2017). https://doi.org/10.1007/s12640-016-9682-9

Download citation

Keywords